Eric Lawrence Simpson
Impact in
- Dermatology top 0.01%
- Dermatology and Skin Diseases
- Contact Dermatitis and Allergies
- Immunology and Allergy top 0.02%
- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
Papers in
- Dermatology 354
- Dermatology and Skin Diseases 341
- Contact Dermatitis and Allergies 22
-
- Allergic Rhinitis and Sensitization 85
- Food Allergy and Anaphylaxis Research 65
- Co-authors
- Jonathan I. Silverberg (102 shared papers)Caroline W. Koudelka (2 shared papers)Andrew Blauvelt (51 shared papers)Amy S. Paller (50 shared papers)Emma Guttman-Yassky (48 shared papers)Lawrence F. Eichenfield (58 shared papers)Jon M. Hanifin (15 shared papers)Tatyana Shaw (1 shared paper)
- Journals
- Journal of the American Academy of Dermatology (63 papers)British Journal of Dermatology (37 papers)Dermatology and Therapy (27 papers)Journal of Investigative Dermatology (20 papers)Journal of the European Academy of Dermatology and Venereology (19 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Eric Lawrence Simpson
359 papers receiving 17.6k citations
Eric Lawrence Simpson's Hit Papers
Peers
Comparison fields: 5 of 138
- Dermatology 14.7k
- Immunology and Allergy 7.2k
- Rheumatology 2.3k
- Physiology 3.2k
- Immunology 1.4k
Countries citing papers authored by Eric Lawrence Simpson
This map shows the geographic impact of Eric Lawrence Simpson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Lawrence Simpson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Lawrence Simpson more than expected).
Fields of papers citing papers by Eric Lawrence Simpson
This network shows the impact of papers produced by Eric Lawrence Simpson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Lawrence Simpson. The network helps show where Eric Lawrence Simpson may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Lawrence Simpson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 386 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis Hit paper breakdown → | 2016 | 1703 |
| 2 | Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health Hit paper breakdown → | 2010 | 616 |
| 3 | Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention Hit paper breakdown → | 2014 | 551 |
| 4 | Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* Hit paper breakdown → | 2020 | 476 |
| 5 | Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults Hit paper breakdown → | 2016 | 465 |
| 6 | Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials Hit paper breakdown → | 2021 | 447 |
| 7 | Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis Hit paper breakdown → | 2019 | 416 |
| 8 | Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Hit paper breakdown → | 2021 | 396 |
| 9 | Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2020 | 390 |
| 10 | Mental health comorbidity in patients with atopic dermatitis Hit paper breakdown → | 2012 | 376 |
| 11 | Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis Hit paper breakdown → | 2021 | 365 |
| 12 | Conjunctivitis in dupilumab clinical trials Hit paper breakdown → | 2019 | 361 |
| 13 | Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis Hit paper breakdown → | 2020 | 323 |
| 14 | Atopic dermatitis in the pediatric population Hit paper breakdown → | 2021 | 316 |
| 15 | Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) Hit paper breakdown → | 2018 | 282 |
| 16 | Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis Hit paper breakdown → | 2020 | 275 |
| 17 | Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study Hit paper breakdown → | 2018 | 272 |
| 18 | 2014 | 257 | |
| 19 | Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Hit paper breakdown → | 2016 | 256 |
| 20 | Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies Hit paper breakdown → | 2021 | 248 |
About Eric Lawrence Simpson
Eric Lawrence Simpson is a scholar working on Dermatology, Immunology and Allergy, Rheumatology, Physiology and Biotechnology, having authored 386 papers that have together received 18.2k indexed citations. Recurring topics across this work include Dermatology and Skin Diseases (341 papers), Allergic Rhinitis and Sensitization (85 papers), Food Allergy and Anaphylaxis Research (65 papers), Asthma and respiratory diseases (59 papers), Urticaria and Related Conditions (48 papers), Contact Dermatitis and Allergies (22 papers), Transgenic Plants and Applications (16 papers) and IL-33, ST2, and ILC Pathways (14 papers). The work is most often cited by research in Dermatology (14.7k citations), Immunology and Allergy (7.2k citations), Rheumatology (2.3k citations), Physiology (3.2k citations) and Immunology (1.4k citations). Eric Lawrence Simpson has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Jonathan I. Silverberg, Caroline W. Koudelka, Andrew Blauvelt, Amy S. Paller, Emma Guttman-Yassky, Lawrence F. Eichenfield, Jon M. Hanifin, Tatyana Shaw, Thomas R.M. Bieber and Jacob Pontoppidan Thyssen. Their work appears in journals such as Journal of the American Academy of Dermatology, British Journal of Dermatology, Dermatology and Therapy, Journal of Investigative Dermatology and Journal of the European Academy of Dermatology and Venereology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.